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lanwpc.2021.100293Introduction Neglected tropical diseases control programmes run separately. For settings with more than one
endemic disease, combined mass drug administration (MDA) has potential practical advantages compared with sep-
arate programmes but needs confirmation of safety. We assessed the safety of combined MDA for multiple neglected
tropical diseases using ivermectin, diethylcarbamazine, albendazole (IDA) and azithromycin (AZI).
Methods We conducted an open-label, cluster-randomized trial involving individuals living in 34 wards (smaller
administrative division) in two study sites, Namatanai District and Lihir Island, Papua New Guinea. We randomly
assigned wards to the combined treatment arm (which received a single dose of the triple combination IDA and a
single dose of AZI at the same visit) or the control arm (which received IDA separately followed by AZI separately
one week after). All participants underwent safety assessments one day after drug administration. Methodology
for collecting the adverse events (AEs) was a general question (in Namatanai) and individual questions about spe-
cific AEs (in Lihir). The primary endpoint was the prevalence of AEs. Safety of combined treatment was taken to
be non-inferior to that of IDA if the upper limit of the two-sided CI for the difference in rates was equal or lower
than 5%.
Findings The study enrolled 15,656 participants. Of those enrolled, 7,281 (46.3%) received the combined regimen
and 8,375 (53.3%) received standard treatment with IDA for lymphatic filariasis between Nov 1, 2018, and Apr 15,
2019. Of the individuals in the control group, 4,228 (50.5%) attended a second visit one week apart to receive AZI
for yaws. In Namatanai, the proportion of AEs was similar in the combined group (0.8%) compared to the IDA
group (1.3%, difference 0.5% [95CI -2.5% to 1.4%]) or the AZI group (3.6%, d -2.8% [95CI -8.6% to 2.8%]). In Lihir,
the proportion of AEs was higher in the combined group (23.0%) compared to the IDA group (12.2%, d 10.8% [95%
CI 1.5% to 20.2%]) or the AZI group (11.1%, d 11.9% [95% CI 2.7% to 21.1%]).We observed 21 (0.3%) grade-2 AEs in
the combined treatment group, 33 (0.4%) in the IDA separately group, and 18 (0.2%) in the AZI separately group.
No participants required treatment for any AE. We observed no deaths, serious AEs, or AEs of special interest.
Interpretation In the largest trial so far involving coadministration of regimens based on IDA and AZI, the combi-
nation was safe and feasible in a population of more than 15,000 people. Combined MDA based on these two regi-
mens opens up new potential for the control of neglected tropical diseases in the Western Pacific region.*Corresponding Author. Dr Lucy Ninmongo John, National Department of Health, Papua New Guinea, +675 301 3736 or
72396952
E-mail addresses: lucyninmongojohn@gmail.com, lucy_john@health.gov.pg (L.N. John).
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Evidence before this study
On Feb 15, 2021, we searched PubMed without lan-
guage restrictions for articles containing the terms
“mass drug administration”, “ivermectin”, “diethylcar-
bamazine”, “albendazole”, and “azithromycin” either in
the title or the abstract. The search returned only two
items: one review analysing literature of these treat-
ments separately, and our previous pharmacokinetic
study assessing the quadruple combination. We found
no evidence on the administration of the quadruple
combination in the field.
Added value of this study
Our trial was designed to investigate the safety of mass
drug administration (MDA) of two integrated therapies
with ivermectin, diethylcarbamazine, and albendazole
(IDA) and azithromycin. To our knowledge, it is the first
published large-scale trial of coadministration of this
strategy to control neglected tropical diseases, provid-
ing safety information on more than 15,000 people. In
our study, safety was evaluated using active monitoring
of adverse events.
Implications of all the available evidence
IDA-based MDA is recommended in countries endemic
for lymphatic filariasis outside sub-Saharan Africa, while
both trachoma and yaws elimination programmes are
based on MDA with azithromycin. Our study provides
evidence that coadministration of IDA and azithromycin
is feasible and safe in a neglected tropical diseases co-
endemic setting. Our findings, therefore, encourage the
strategy of integration of MDA for neglected tropical
diseases sharing similar target populations and thera-
pies to reduce costs and allow a more rapid scale-up of
programmes.Introduction
Mass drug administration (MDA) is the mainstay of
control programs for many neglected tropical diseases
(NTDs), including lymphatic filariasis, soil-transmitted
helminths, trachoma, and yaws.1−3 In most countries,
NTD control programs typically run separately and
deliver separate MDA campaigns for each targeted dis-
ease. Integration of activities has been highlighted as a
priority in the World Health Organization Roadmap for
NTDs.4 MDA campaigns are one area where integrationmay reduce economic and logistic costs and potentially
reduce complexity.5
Papua New Guinea is endemic for a number of
NTDs targeted for elimination or eradication through
MDA, including lymphatic filariasis, soil transmitted
helminths (STH), trachoma, yaws, and scabies.6−8 For
the last 20 years, the main strategy for lymphatic filaria-
sis elimination has consisted of repeated rounds of
MDA with albendazole and either diethylcarbamazine
or ivermectin. However, recent studies have shown that
single-dose combination therapy with all three
drugs¡ivermectin, diethylcarbamazine, and albenda-
zole (IDA)¡is superior to the previous two-drug combi-
nations, and may help accelerate lymphatic filariasis
elimination.1 In light of the emerging data on both,
safety and efficacy of the triple
combination, the WHO has provided alternative guide-
lines recommending IDA-based MDA in countries
endemic for lymphatic filariasis outside sub-Saharan
Africa.9 IDA-based MDA for lymphatic filariasis is also
likely to reduce the prevalence of both STH and
scabies.10,11
Public health programmes for both trachoma,
caused by serovars A, B, and C of Chlamydia trachoma-
tis, and yaws, caused by Treponema pallidum subsp. per-
tenue, are based on MDA with the macrolide antibiotic
azithromycin (AZI).2,3
Programmatic adoption of integrated MDA requires
both pharmacokinetic data on any drug interactions and
field studies evaluating the safety of integrated MDA.
We recently reported the results of a clinical study that
compared the pharmacokinetics of administration of
IDA separately (lymphatic filariasis regimen) or AZI
separately (yaws regimen) with coadministration of IDA
and AZI (combined treatment regimen). Compared to
separately administered treatment, the study demon-
strated an absence of clinically relevant drug-drug inter-
actions, and no severe adverse events (AE) were
observed.12 These findings paved the way for more
extensive field studies to evaluate the safety of integrated
MDA. In this study, we aimed to assess the safety of a
large-scale administration of the combined treatment
regimen for lymphatic filariasis and yaws.Methods
Study setting and participants
We conducted a cluster-randomized controlled trial in
four local level government (LLG) areas in the New Ire-
land Province in Papua New Guinea (PNG): three inwww.thelancet.com Vol xx Month xx, 2021
Figure 1. Study Map
Articlesthe Namatanai District in the island of New Ireland
(Matalai Rural LLG, Namatanai Rural LLG, and Sentral
Niu Ailan Rural LLG), and one in the Lihir Island
(Nimamar Rural LLG) (Figure 1). Clusters were individ-
uals living in the same ward, which is the smaller
administrative unit in PNG. A ward consists of 500-
1,000 persons living in a group of neighbouring villages
that generally share a school or church. Each LLG in the
study area has between 7-21 wards that are identified
with consecutive numbers. We randomized 34 wards
(19 in Namatanai and 15 in Lihir) to either an experi-
mental arm or a control arm. The intervention first
started in Namatanai District alongside two public
health campaigns: a trial designed to assess the effec-
tiveness of an MDA strategy to eliminate yaws at the
population level (NCT 03490123); and an MDA round
with IDA, launched by the National Department of
Health for the elimination of lymphatic filariasis. Due
to a lower-than-expected enrolment in Namatanai, the
study was expanded to Lihir Island alongside the ongo-
ing rollout of IDA by the National Department of
Health. The study was conducted in November 2018
(Namatanai) and April 2019 (Lihir).
All individuals older than 6 months and living in the
study area were eligible to participate. Contraindications
for individual drugs were in line with PNG National
Department of Health guidelines for MDA, which
include concomitant use of medications contraindicated
with any MDA drug, and pregnancy (verbally declared)
or breastfeeding. Participants who were unable to take
oral medication and those who did not give informed con-
sent or who withdrew consent were also excluded. Supple-
mentary file 1 provides a detailed list of exclusion criteria.www.thelancet.com Vol xx Month xx, 2021The study was approved by Medical Research Advisory
Committee of Papua New Guinea (MRAC 17.19). The
ethics committee approved the use of oral consent.Randomization and interventions
Randomization was performed at the level of the ward
and stratified by study site (i.e., Namatanai and Lihir). A
randomisation sequence was generated using R and a
block size of 4. Wards were randomized to receive one
of two treatment regimens: in the experimental arm, vil-
lages received a single visit at which time a combined
MDA for lymphatic filariasis and yaws were conducted
consisting of IDA and AZI at the same time. In the con-
trol arm, villages received an initial visit at which time
MDA for lymphatic filariasis was conducted with IDA,
and then one week later a second visit when MDA for
yaws was conducted with AZI. All drugs were adminis-
tered orally at standard dosing according to age (Table
S1, Supplementary File 1) and in line with the WHO
guidelines of MDA for lymphatic filariasis and yaws,
respectively. All treatment was directly observed. AZI
was provided free of charge by Kern Pharma Spain; iver-
mectin, diethylcarbamazine, and albendazole were
donated through WHO to the National Department of
Health of Papua New Guinea. Blinding of trial partici-
pants and outcome assessors was not possible as the
intervention was embedded within programmatic
MDA.Study oversight
The field teams consisted of one community health
worker (CHW) and 4 village health volunteers, all3
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supervised by the study research team, which consisted
of three senior researchers. CHWs were given mobile
phones for regular communication with the research
team. All study personnel received training on data col-
lection and AE reporting in both study islands.
Field teams visited candidate villages and met
community leaders to explain the study purpose and
procedures. Before any procedure, adult partici-
pants¡parents, or guardians for participants younger
than 18 years¡provided verbal consent to participate.
Individuals who consented to receive the regimen and
enter the study were asked to attend the village clinic or
community hall to receive treatment on an agreed date.
Study drugs were delivered by field teams as part of the
National Department of Health lymphatic filariasis pro-
gram; in villages allocated in the control arm, an addi-
tional visit was scheduled one week after to deliver the
dose of the AZI regimen for yaws.Outcomes
The primary safety endpoint was the prevalence of self-
reported AEs, defined as the proportion of participants
who experienced at least one treatment-related AE fol-
lowing drug administration. Other endpoints included
the occurrence of any serious AE (i.e., grade 3-to-4 toxic-
ity). The onset of AEs was assessed by active surveil-
lance using individual structured interviews conducted
in Tok Pisin by field teams who remained in the villages
for 24 hours after drug administration.
In Namatanai, field teams assessed the occurrence of
AEs by asking an open-ended question (“Since the last
visit, have you experienced any medical problem?”) as part
of the routine follow-up. Participants who answered in the
positive were asked to identify the type of condition from a
standardized list. Following enrolment in Namatanai, we
noted a relatively low proportion of individuals reporting
AEs across the whole study population. Therefore, when
we expanded the study to Lihir, we switched to explicitly
asking participants about each symptom individually.
Answers in the positive in any of the questionnaire items
were recorded in a clinical report form as an AE.
Regardless of methodology, for all AEs identified, the
field teams gathered information regarding duration
(i.e., start and end date), relationship with study drugs,
severity, action taken, and outcome. AE severity was
graded on a 1-4 scale using the GRADE system estab-
lished in the Common Terminology Criteria for Adverse
Events version 4.0. Participants with grade ≥2 AEs were
examined by a study clinician. Whenever possible if
appropriate, additional diagnostic testing and/or treat-
ments could be provided free of charge to participants.
Causality was graded using the following categories:
related, not related, and not assessable. For the primary
endpoint analysis, we included all AEs graded as
“related” in the causality assessment. The study was reg-
istered on clinical trials.gov (NCT03676140).Statistical Analysis
This study was based on the hypothesis that combined
treatment would be non-inferior to separate MDA for the
primary safety endpoint, according to a prespecified non-
inferiority margin: the upper limit of the 95% confidence
interval (CI) for the difference in AE rates would not exceed
5%. We compared combination MDA to both IDA and
AZI separately. We originally calculated that 32 clusters of
450 individuals (sample size of 14,400 - 7,200 per group)
would give a power of 80% to test the hypothesis of non-
inferiority, assuming that 10% of participants would be lost
to follow-up. This sample size accounted for an expected
non-serious AEs rate of IDA of 10%, a non-inferiority mar-
gin of 5%, a one-sided type 1 error rate of 0.05, and a kappa
value of 0.35. In addition, our large sample size provides
power to detect rare AEs which might not be detected in
smaller studies. As enrolment was lower than anticipated,
we expanded the study to enrol additional clusters in Lihir.
The primary analysis was a per-protocol analysis which
included all individuals who received the planned dose of
the assigned drug, either IDA separately or AZI separately
compared to combined treatment (i.e., coadministration of
IDA and AZI), and responded to the AE questionnaire.
Based on the existing safety profile of the drugs we
assumed that nearly all adverse events would occur within
a 24hr window following MDA.We therefore opted to con-
sider each AE following each MDA separately. We calcu-
lated the proportion of individuals who experienced an AE
after combined MDA, in the intervention arm, and for the
proportion of individuals who experienced an AE after
either the initial MDA (for lymphatic filariasis) or the sec-
ondMDA (for yaws) in the control arm.
The frequency of AEs was described as the number
of participants experiencing an AE and the percentage.
Robust standard errors were used to adjust for cluster-
ing. We fitted a random-effects regression model which
adjusted for clustering at the level of the ward to assess
whether treatment arm was associated with the risk of
experiencing an AE. Initially we had planned to conduct
a single analysis combining data across the two sites.
However, as the methods for eliciting AEs differed and
this appeared to be associated with markedly different
rates of reporting of AEs across the study sites we opted
post-hoc to present analyses for the Namatanai and
Lihir settings separately. Overall results are included in
the Supplementary appendix.
The prevalence of participants with AEs, AEs grade, and
“related” causality were calculated with the 95% CI and
presented in the table format, grouped according to treat-
ment: combined MDA with IDA and AZI, IDA separately,
and AZI separately. We calculated an exact binomial CI to
estimate the proportion of grade 3-4 NIH-NCI toxicity.Role of the funding source
The funders had no role in the study design, data collec-
tion, data analysis or interpretation of data, or in writingwww.thelancet.com Vol xx Month xx, 2021
Figure 2. Trial profile
The study area consisted of three Local Level Government (LLG) areas in Namatanai District and one LLG in Lihir Island. We
selected wards that were eligible to receive both yaws and LF MDA: 4 wards out of 7 in Matalai Rural LLG, 7 wards out of 15 in Nama-
tanai Rural LLG, 8 wards out of 21 in Sentral Niu Ailan LLG, and all 15 wards in Nimamar LLG.
IDA: ivermectin, diethylcarbamazine, and albendazole.MDA:mass drug administration.
Articlesof the manuscript or decision to submit for publication.
The corresponding author had full access to all the data
in the study and had final responsibility for the decision
to publish.Results
Between Nov 1, 2018, and Apr 15, 2019, 15,656 individu-
als from 34 wards met the inclusion criteria and provided
verbal informed consent to participate in the study: 5,794
in Lihir, and 10,378 in Namatanai. Of them, 7,281
(46.3%) lived in wards allocated to the experimental arm
and received the combined MDA with IDA plus AZI,
and 8,375 (53.3%) lived in wards allocated to the control
arm and started standard MDA with IDA for lymphatic
filariasis (Figure 2). Of the individuals in the control arm,
4,228 (50.5%) attended a second visit one week apart to
receive AZI. Table 1 summarizes the main characteristics
of study participants and their distribution across treat-
ment groups and settings.www.thelancet.com Vol xx Month xx, 2021In Lihir, the primary outcome was observed in 461
(23.0%) of 2,003 participants in the combined treat-
ment group, 462 (12.2%) of 3,796 participants in the
IDA group (absolute difference 10.8% [95% CI 1.5% to
20.2%]) and 389 (11.1%) of 3,496 participants in the
AZI group (absolute difference 11.9% [95% CI 2.7% to
21.1%]). In Lihir, therefore, the non-inferiority criterion
was not met for the primary safety outcome at 24 hours
after combined drug administration compared to either
IDA or AZI separately (Table 2).
In Namatanai, the primary outcome was observed in
42 (0.8%) of 5,278 participants in the combined treat-
ment group, 62 (1.3%) of 4,650 participants in the IDA
group (absolute difference -0.5% [95% CI -2.5% to
1.4%]) and 26 (3.6%) of 732 participants in the AZI
group (absolute difference -2.8% [95% CI -8.6% to
2.8%]). In Namatanai, therefore, the non-inferiority cri-
terion was met for the primary safety outcome at
24 hours after combined drug administration compared







Male 3,465 (47.6%) 4,364 (52.1%) 2,107 (49.8%)
Female 3,816 (52.4%) 4,011 (47.9%) 2,121 (50.2%)
Age 18 (8-34) 18 (9-33) 18 (9-31)
Study site
Lihir 2,003 (27.5%) 3,791 (45.3%) 3,496 (82.7%)
Namatanai 5,728 (78.7%) 4,584 (54.7%) 732 (17.3%)
Table 1: Participant characteristics at baseline
IDA: ivermectin, diethylcarbamazine, and albendazole. MDA: mass drug
administration.
a Coadministration of IDA and azithromycin.
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In a random-effects regression analysis comparing
combined treatment with IDA separately, older age and
female gender were associated with an increased likeli-
hood of reporting an AE (Table 3). When comparing
combined therapy with AZI separately we also found an
association with female gender, but not age, on the like-
lihood of reporting an AE.
Table 4 summarizes the frequency and type of AEs
associated with each treatment regimen. Fatigue was
the AEs most frequently reported after combinedCombination
MDAa
IDA A
Lihir N=2,003 N=3,796 N=
Participants reporting an adverse
event, n (%)
461 (23.0%) 462 (12.2%) 389
Namatanai N=5,278 N=4,650 N=
Participants reporting an adverse
event, n (%)
42 (0.8%) 62 (1.3%) 26
Table 2: Trial outcomes
CI: confidence interval. IDA: ivermectin, diethylcarbamazine, and albendazole.M
a Coadministration of IDA and azithromycin.
Combination MDA vs IDA p value
By Study Site
Lihir
Age (by 5-year increment) 1.06 (1.04 -1.09) <0.0001
Male Gender 0.79 (0.68 - 0.92) 0.002
Combination MDA 2.45 (1.33 - 4.52) 0.004
Namatanai
Age (by 5-year increment) 1.07 (1.00-1.14) 0.040
Male Gender 0.65 (0.44-0.97) 0.001
Combination MDA 0.31 (0.02 -4.99) 0.400
Table 3: Random-effects regression analysis of variables associated wit
IDA: ivermectin, diethylcarbamazine, and albendazole.MDA: mass drug adminis
aCoadministration of IDA and azithromycin.treatment (298/7,281; 4.1%) and IDA (248/8,441;
3.0%), whereas abdominal pain was the leading AE
associated with AZI (191/4,228; 4.6%). The percentage
of individuals reporting AEs in each cluster ranged
from 0 to 60% (mean 12%; SD 14%).
AEs reported in the study were mostly Grade 1 and
self-limiting. We observed 21 (0.29%) Grade-2 AEs in
the combined treatment group, 33 (0.39%) in the IDA
separately group, and 18 (0.21%) in the AZI separately
group (Table S2). No participants required treatment
for any AE. We observed no deaths, serious AEs, or AEs
of special interest.Discussion
In this cluster-randomized trial we found markedly dif-
ferent AE rates across our two study sites. In Namatanai
coadministration appeared to meet the non-inferiority
margin but in Lihir the rate of AEs was higher in the
experimental arm and did not meet the prespecified
non-inferiority margin compared with standard IDA
separately. This reflects both the different methods
used for eliciting AEs across study sites and the lower







(11.1%) 10.8% (1.5 to 20.2%) 11.9% (2.7 to 21.1%)
732
(3.6%) -0.5% (-2.5% to 1.4%) -2.8% (-8.6% to 2.8%)
DA: mass drug administration. AZI: azithromycin.
Combination MDA vs Azithromycin p value
0.99 (0.96-1.02) 0.450
0.76 (0.65 - 0.89) <0.001
2.26 (1.2 - 4.2) 0.010
1.03 (0.95 - 1.11) 0.470
0.92 (0.56 - 1.49) 0.720
0.16 (0.008 - 3.11) 0.227
h adverse events
tration.








Any Adverse Event 503 (6.9%) 524 (6.3%) 415 (9.9%)
Fever 15 (0.3%) 32 (0.4%) 43 (1.1%)
Headache 23 (0.4%) 49 (0.6%) 43 (1.1%)
Abdominal Pain 144 (2%) 83 (1%) 191 (4.6%)
Diarrhoea 138 (1.9%) 29 (0.3%) 74 (1.8%)
Nausea 62 (0.9%) 33 (0.4%) 66 (1.6%)
Vomiting 50 (0.7%) 29 (0.4%) 55 (1.4%)
Myalgia 12 (0.2%) 19 (0.3%) 32 (0.8%)
Rash 1 (0.1%) 2 (0.1%) 26 (0.7%)
Itching 2 (0.1%) 6 (0.1%) 1 (0.1%)
Cough 6 (0.1%) 5 (0.1%) 18 (0.5%)
Shortness of Breath 1 (0.1%) 3 (0.1%) 18 (0.5%)
Limb Swelling 1 (0.1%) 2 (0.1%) 17 (0.5%)
Painful
Lymphadenopathy
3 (0.1%) 6 (0.1%) 0 (0%)
Fatigue 298 (4.1%) 248 (3.0%) 104 (2.5%)
Dizziness 39 (0.6%) 166 (2.0%) 57 (1.4%)
Allergic Reaction 2 (0.1%) 2 (0.1%) 1 (0.1%)
Table 4: Adverse events reported by participants
IDA: ivermectin, diethylcarbamazine, and albendazole. MDA: mass drug
administration.
aCoadministration of IDA and azithromycin.
Articlescombined MDA resulted in higher proportion of AEs
(23%) than either of the separate MDAs (11%), overall,
the addition of proportions of the two separate MDAs
was similar to the combined MDA. It is unclear both
programmatically and from a community acceptance
perspective whether it would be preferable for commu-
nities to experience 20% adverse events at a single time
point, or two distinct rounds each of which generate
10% AEs. Reassuringly, AEs in both groups were mild.
The most common AEs reported were fatigue and dizzi-
ness in the IDA group, gastrointestinal in the AZI
group, and all the mentioned three AEs in the combined
treatment arm. These AEs are in line with commonly
reported side-effects following MDA in other settings.
The lack of any serious AEs in a population of more
than 15,000 people, and the small number of AEs, indi-
cate that coadministration is a viable means of integrat-
ing programmes to control multiple, co-endemic
neglected tropical diseases.
Whilst we did not formally set out to compare cover-
age achieved by a combination MDA to separate MDA,
we noted a markedly reduced level of coverage achieved
in the AZI MDA conducted one week after IDA MDA,
highlighting the difficulty in reaching high levels of
compliance in repeated rounds of MDA in remote and
rural villages. Reasons for non-compliance to the second
round included programme fatigue for longer-running
treatment programmes, and other behavioural factors
like the need of villagers to prioritize their daily activitieswww.thelancet.com Vol xx Month xx, 2021for subsistence. Coadministered MDA may overcome
these barriers and offer programmes significant logistic
advantages.
Our study has a number of limitations. Firstly, enrol-
ment was lower than anticipated, which reduced our
power to demonstrate non-inferiority. In particular, a
much smaller number of individuals received separate
MDA with AZI in Namatanai. Because our study was
embedded in programmatic roll-out of MDA we do not
have detailed demographic data on individuals who did
not attend for the azithromycin MDA or on why they
opted to not attend for the second MDA. However, our
study is still the largest ever evaluating this approach
and provides valuable information to guide NTD pro-
grammes. Secondly, due to a low rate of AEs noted in
Namatanai District, we altered the approach to asking
participants about the side effects of MDA. We found
that using a checklist of common side effects yielded up
to 10 times more AEs than did an open-ended question.
The latter method might have missed mild, transient
AEs that had been forgotten by participants at the time
they were interviewed 24 hours later. Besides being a
limitation of our study, this finding highlights the diffi-
culties in collecting high-quality AE data alongside pro-
grammatic MDA. The lower rates of AEs reported in
Namatanai are broadly consistent with those obtained
in a study evaluating combined MDA with ivermectin
and azithromycin in the Solomon Islands13 but much
lower than reported in studies in Mali evaluating com-
bined ivermectin, azithromycin, and albendazole
MDA.14 These findings, together with our observation
suggest many individuals do not report mild, self-limit-
ing AEs unless asked specific questions. The impor-
tance of such AEs requires further study. We observed
individuals only for 24 hours following MDA. This is
broadly in keeping with other studies assessing safety of
MDA. Whilst we may have missed some late AEs, in the
context of a single dose MDA treatment the vast major-
ity of AEs are expected to occur within the first 24 hours,
and we therefore do not believe this will have substan-
tially altered our findings. As the study was embedded
alongside programmatic MDA blinding was not possible
and this should be considered in future studies to reduce
the risk of reporting bias. We focused only on safety and
not efficacy but as we have previously demonstrated an
absence of clinically significant pharmacokinetic interac-
tions, we do not anticipate that the efficacy of combined
would be reduced compared to separate MDA.
In summary, our study provides critical data on the
programmatic implementation of combined MDA with
IDA and AZI compared to separate MDA. Although the
AEs rate did not achieve the prespecified non-inferiority
margin, the absence of any increase in severe AEs, and
higher coverage observed with combined MDA provide
some encouragement for implementing this strategy.
Further data, either in the context of studies or collected
alongside programmatic rollout, will help WHO and7
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